Ireland· IE-PA-EU/1/15/1035/001-003
OBIZUR 500 U powder and solvent for solution for injection
A susoctocog alfa product containing susoctocog alfa, registered in Ireland by Baxter Innovations GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Susoctocog alfa is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BD14 (susoctocog alfa), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Susoctocog alfa · ATC B02BD14
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
The record
At a glance
HPRA (Ireland)- Active substance
- Susoctocog alfa
- Manufacturer
- Baxter Innovations GmbH
- Country
- Ireland (IE)
- ATC code
- B02BD14
- ATC class
- Susoctocog alfa
- Defined daily dose
- 14 TSD, E
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/15/1035/001-003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Susoctocog alfa in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaOBIZURBaxalta Innovations GmbH, Vídeň
- SpainOBIZUR 500 U POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEBaxalta Innovations Gmbh
- FinlandObizurBaxalta Innovations GmbH
- FranceOBIZUR 500 U, poudre et solvant pour solution injectableBAXALTA INNOVATIONS (AUTRICHE)
- United KingdomObizur 500unit powder and solvent for solution for injection vialsTakeda UK Ltd
- IcelandObizurBaxalta Innovations GmbH
- Japanスソクトコグ アルファ（遺伝子組換え）武田薬品工業
- NetherlandsObizur 500 U poeder en oplosmiddel voor oplossing voor injectieBaxter Innovations GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Obizur
- Liechtenstein · Obizur
- Norway · Obizur
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8a6ef7d4-57c2-49c3-9327-8bb148c26a83 GET /v1/drugs/8a6ef7d4-57c2-49c3-9327-8bb148c26a83?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder and solvent for solution for injection",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"B02BD",
"B02BD14"
],
"strength": null,
"pa_number": "EU/1/15/1035/001-003",
"substances": [
"Susoctocog alfa"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about susoctocog alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.